researchintokyo.com

Japan Market Access

Japan Market Access

  • Home
  • Japan Market Access
    • Coverage Decisions
    • Pricing and Reimbursement
  • Approvals
    • List of New Drugs/Indications Approved in Japan in 2014
  • Services
    • Marketing Authorization
  • Blog
  • About Us
  • Contact Us

Recent Posts

  • Protected:
  • Anti-VEGF Battles: Eylea Overtakes Lucentis in Japan
  • iPS Cell Regenerative Medicine to Rely on Donor Cells in Order to Cut 77% of Costs
  • Plan: Generics to increase from 60% to 80% by 2017
  • Average Nursing Care Premium Breaks Through ¥5000

Protected:

This entry was posted in Uncategorized and tagged CGRP japan approval migraine new drugs on April 12, 2020 by RIT (updated 1715 days ago)

This content is password protected. To view it please enter your password below:

Post navigation

  • ← Anti-VEGF Battles: Eylea Overtakes Lucentis in Japan

· © 2024 researchintokyo.com · Designed by Press Customizr · Powered by ·